Luke Greenwalt, MBA, vice president and lead, IQVIA Market Access Center of Excellence, has joined the editorial advisory board of Managed Healthcare Executive.

Artificial intelligence is quickly becoming a valuable tool in the U.S. healthcare industry. Experts say a thoughtful approach can head off ethical problems and optimize efficiency.

UnitedHealthcare is adding deductibles to Part D prescriptions on certain formulary tiers as a result of plan design changes from the Inflation Reduction Act.

Although many women are living longer after a breast cancer diagnosis, inequalities persist.

Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.

Payers and providers are figuring out ways to overcome the transportation barriers that get in the way of people receiving healthcare.

Sean M. Oser, M.D., M.P.H., an associate professor in the Department of Family Medicine at the University of Colorado School of Medicine, discussed diabetes management and quality measures in a Managed Healthcare Executive K-Cast video series.

Individual coverage health reimbursement arrangements (ICHRAs) let employees pick their health insurance policy.

Previous research has shown an association between atopic dermatitis and obesity. But these findings elaborate on that observation and point to a connection to abnormal lipid metabolism and elevated "bad" LDL cholesterol levels.

A study in mice finds that blocking somatostatin could restore the ability of the pancreas to release glucagon in the event of low blood sugar.

Preclinical data had suggested reducing serotonin might improve symptoms of pulmonary arterial hypertension, but new phase 2b data suggest the opposite.

Black patients are less likely than White patients to get the molecular testing that can led to immunotherapy and other more advanced treatments.

Some study results tempered enthusiasm for one digital therapeutic but others are showing promising if early results.

Less than a quarter of menopausal women have their menopause symptoms entered into their charts at primary care visits, resulting in missed opportunities for timely treatment.

Treatment with Entyvio (vedolizumab), an integrin receptor antagonist, followed by Humira (adalimumab), a tumor necrosis factor blocker, resulted in the lowest overall incidence of adverse events, according to an industry-sponsored study.

Sen. J.D. Vance credited Donald Trump with "salvaging" the Affordable Care Act (ACA). Gov. Tim Walz said Trump worked to repeal the ACA and Vance has proposals that would bring back pre-ACA limitations on health insurance for people with preexisting conditions.

With this year's Breast Cancer Awareness Month now underway, we are sharing eight facts and updates about breast cancer that you might not know about.

In 2025, Aetna will merge its three stand-alone prescription drug plans into a single plan and member cost-shares will be consistent at every pharmacy within its network.

Otulfi is the fourth Stelara biosimilar to be approved by the FDA.

Blue Shield of California is purchasing Idacio for a net price of $525 per monthly dose, and most plan members will pay $0 out of pocket.

VX-880 is an allogeneic stem cell-derived islet cell therapy that has been able to control blood glucose as well as natural human islets in a small group of patients with type 1 diabetes.

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and a large number of clinical trials enrolling people with the condition.

Here’s what you missed this week on Managed Healthcare Executive.

This is the sixth indication for Dupixent and the only biologic approved in the United States to treat COPD.

The Democrats have expanded the program under the Affordable Care Act. Republicans have proposed cuts in federal funding and work requirements.